Official UK procurement notice
Supply and Manufacture of Investigational Medicinal Products (IMPs) for the Clinical Trial: "Examining Antibiotics for Ulcerated Skin Cancer Surgical Excision"
Authority: NHS Wales Shared Services Partnership (NWSSP) - Procurement Services (NHS & healthcare)
What is being bought
Published requirement descriptionCardiff and Vale University Health Board (CAVUHB) is undertaking a clinical trial entitled ‘Examining Antibiotics for Ulcerated Skin Cancer Surgical Excision’, funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment Programme (Ref: NIHR 160872). As part of this clinical trial, an Investigational Medicinal Product (IMP) needs to be manufactured and distributed.
CPV: Medical equipments, pharmaceuticals and personal care products
The lotProcurement structure
single lot · no lot value publishedLot #1Supply and Manufacture of Investigational Medicinal Products (IMPs) for the Clinical…
Supply and Manufacture of Investigational Medicinal Products (IMPs) for the Clinical Trial: "Examining Antibiotics for Ulcerated Skin Cancer Surgical Excision"
Cardiff and Vale University Health Board (CAVUHB) is undertaking a clinical trial entitled ‘Examining Antibiotics for Ulcerated Skin Cancer Surgical Excision’, funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment Programme (Ref: NIHR 160872). As part of this clinical trial, an Investigational Medicinal Product (IMP) needs to be manufactured and distributed. The IMPs required are:
-Flucloxacillin 2 x 500mg capsules, over encapsulated
-A matching placebo of inert filler, over encapsulated to match flucloxacillin 2 x 500mg capsules.
The successful supplier will be responsible for the manufacture, packaging, labelling, Quality Assurance (QA) certification, storage, shipment, and regulatory compliance (CTIMP regulations) associated with the trial’s IMPs.
After extensive market research and consultations with multiple suppliers, it has been concluded that only one supplier, Simbec-Orion, has the capability to fulfil the full scope of the contract requirements. This includes:
-Over encapsulation of flucloxacillin and matching placebo
-Packaging and labelling of the final product
-Compliance with clinical trial regulations (CTIMP)
-Storage and shipment logistics to participating NHS sites
-QA certification and regulatory compliance for blinded clinical trials
Simbec-Orion will also source the bulk IMP (4 lots of flucloxacillin, 1 lot of placebos), over encapsulate the product, and ensure all necessary documentation and quality assurance procedures are met.
Simbec-Orion is uniquely positioned to meet the requirements of the clinical trial due to its established capabilities in the manufacture and regulatory compliance of Investigational Medicinal Products (IMPs). No other supplier was found to be able to offer the complete set of services required for this project.
Procedure terms & legal framework
From the official record · publisher note attached- Procedure method
- Negotiated without publication of a contract notice
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Competitive procedure
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- Unspecified in notice
- First published
- 20 Jan 2025, 12:02 GMT
- Last source update
- 20 Jan 2025, 12:02 GMT
- FTS notice number
2025/S 000-001841- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-04d494Find a Tender
- Why no open competition
The products involved are manufactured purely for the purpose of research, experiment, study or development under the conditions stated in the directive
- Published justification
The products involved are manufactured purely for the purpose of research. In addition, Simbec-Orion is positioned to meet the requirements of the clinical trial. No other supplier was found to be able to offer the complete set of services required for this project.
Publisher note: NHS Wales Shared Services Partnership are publishing this notice on behalf of; Cardiff and Vale University Health Board Woodland House Maes-y-Coed Road Cardiff CF14 4HH A standstill period of 10 calendar days from publication of this notice will be observed by the authority prior to entering into a contract. NOTE: To register your interest in this notice and obtain any additional information please visit the Sell2Wales Web Site at https://www.sell2wales.gov.wales/Search/Search_Switch.aspx?ID=147495. (WA Ref:147495)
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| SIMBEC RESEARCH LIMITEDSME | £116,645 † | — | Awarded |
Contracts
Contract 001841-2025-CAV-VEA (24-25) 169-1 · SIMBEC RESEARCH LIMITEDSME
- Signed
- 1 Jan 2025
- Value
- £116,645
- Status
- active
Contracting authority & participating public bodies
Dispute resolution & review bodies
- High CourtReview body
Bidders & participating suppliers
1 commercial party on the notice- SIMBEC RESEARCH LIMITEDAwarded supplier
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.